Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Hilger

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Investigational New Drugs|December 21, 2010
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancerDirk Strumberg, Beate Schultheis, M E Scheulen, et al.
British Journal of Cancer|January 18, 2014
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumorsS Bauer, R A Hilger, T Mühlenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2006
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumorsH Richly, B F Henning, P Kupsch, et al.
Bone Marrow Transplantation|December 14, 2004
Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complicationsD W Beelen, R Trenschel, J Casper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2000
Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignanciesM E Scheulen, R A Hilger, C Oberhoff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)M Joerger, J von Pawel, S Kraff, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Investigational New Drugs|December 21, 2010
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancerDirk Strumberg, Beate Schultheis, M E Scheulen, et al.
British Journal of Cancer|January 18, 2014
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumorsS Bauer, R A Hilger, T Mühlenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2006
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumorsH Richly, B F Henning, P Kupsch, et al.
Bone Marrow Transplantation|December 14, 2004
Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complicationsD W Beelen, R Trenschel, J Casper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2000
Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignanciesM E Scheulen, R A Hilger, C Oberhoff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)M Joerger, J von Pawel, S Kraff, et al.
Pageof 3